integument
• marker analysis indicates a perturbed basal-to-suprabasal transition
|
• expanded suprabasal layer as indicated by an increase in Keratin 10-postive cells
|
• increase in the number of epidermal cell layers at 8 weeks of age
|
skin lesions
(
J:199362
)
• progressive development of multiple dermal lesions after weaning
|
thick skin
(
J:199362
)
• at 8 weeks of age
|
• multiple cutaneous hamartomas are seen all over the body within 12 weeks of age
• median onset of disease is 62 days
• mice treated with BKM120, a pan-class I PI3K inhibitor, beginning at 3 weeks of age, do not develop PTEN hamartoma tumor syndrome skin lesions; removal of BKM120 results in development of lesions, indicating that continuous treatment is required
• mice with advanced multiple skin hamartomas treated with BKM120 show improved skin conditions
|
• papillomatous lesions around the facial orifices, ears, and paws, with most associated with hyperkeratosis
|
neoplasm
• multiple cutaneous hamartomas are seen all over the body within 12 weeks of age
• median onset of disease is 62 days
• mice treated with BKM120, a pan-class I PI3K inhibitor, beginning at 3 weeks of age, do not develop PTEN hamartoma tumor syndrome skin lesions; removal of BKM120 results in development of lesions, indicating that continuous treatment is required
• mice with advanced multiple skin hamartomas treated with BKM120 show improved skin conditions
|
• papillomatous lesions around the facial orifices, ears, and paws, with most associated with hyperkeratosis
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
Cowden syndrome | DOID:6457 |
OMIM:PS158350 |
J:199362 |